Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Dr Reddy's: Yet another disappointment - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Oct 27, 2004

    Dr Reddy's: Yet another disappointment

    Introduction to results
    Domestic pharmaceutical major, Dr. Reddy’s, has declared its 2QFY05 results. The topline of the company has grown marginally, owing to poor sales in generics and bulk drug segments. The bottomline of the company is lower by 48% due to very high increase in operational expenses, depreciation and interest outgo.

    (Rs m) 2QFY04 2QFY05 Change 1HFY04 1HFY05 Change
    Net sales 5,236 5,242 0.1% 9,925 9,924 -0.0%
    Expenditure 4,102 4,545 10.8% 7,682 8,898 15.8%
    Operating profit (EBDITA) 1,134 697 -38.5% 2,243 1,026 -54.2%
    Operating profit margin (%) 23.8% 13.3%   22.6% 10.3%  
    Other income 225.1 139.4 -38.1% 446.7 298.6 -33.1%
    Interest 4.1 17.4 324.4% 7.7 65.4 749.4%
    Depreciation 249.2 312.1 25.2% 480.2 589.9 22.8%
    Profit before tax 1,106 507 -54.1% 2,202 669 -69.6%
    Tax 217.4 42.9 -80.3% 436.5 45.9 -89.5%
    Profit after tax/(loss) 889 464 -47.7% 1,766 624 -64.7%
    Net profit margin (%) 17.0% 8.9%   17.8% 6.3%  
    No. of shares (m) 76.5 76.5   76.5 76.5  
    Diluted earnings per share (Rs)* 46.4 24.3   44.2 16.3  
    P/E ratio (x)         44.2  
    (* annualised)            

    What’s the company’s business?
    Dr. Reddy's Laboratories is a leading pharmaceutical company in the country, which is present in the entire pharmaceutical chain - basic research, finished dosages, generics, bulk actives, biotechnology and diagnostics. The company has filed 64 patents and is the first Indian company to out license a molecule for clinical trial. The company is also the first company from India to get an Exclusive Marketing Right (EMR) in the US market for Fluxotine Axetil. The company exports bulk drugs, branded and generic formulations to over 60 countries. In FY04, export contributions to total revenues was 65%. Active Pharmaceutical ingredients (API's) constituted 40% of the company's business in FY04. Formulations business is another big contributor to revenues (39%). Its generics business in regulated markets contributes 22% and the rest comes from diagnostic, critical care and biotechnology business. The company is passing through a rough phase over the last few quarters, where profitability and sales growth have come under pressure.

    What has driven performance in 2QFY05?
    Sales:  The company's revenues have remained stagnant in 2QFY05, which is due to a huge fall in generics sales in the US market (down 16%). This drop in sales can largely be attributed to intense competition in the US market. Also, sales of Fluxotine, and Tizinadine, which were the mainstay of the company in the US market, saw a decline of 41%, as new players launched generic versions of their own. The company has not got any Para IV success after the initial success of Fluxotine. Lack of new launches has also added to the woes of the company. However, the revenues from these products saw an increase of 42% QoQ, when compared to 1QFY05.

    Segmental revenues*
      2QFY04 2QFY05 Change
    API's 2,021 1,821 -9.9%
    (as % of sales) 37.6% 33.7%  
      India 660 553 -16.2%
    (as % of sales) 12.3% 10.2%  
      International 1,361 1,268 -6.8%
    (as % of sales) 25.3% 23.5%  
    Branded formulation 1,971 2,315 17.5%
    (as % of sales) 36.7% 42.8%  
      India 1,395 1,345 -3.6%
    (as % of sales) 25.9% 24.9%  
      International 576 970 68.4%
    (as % of sales) 10.7% 17.9%  
    Generics 1,243 1,043 -16.1%
    (as % of sales) 23.1% 19.3%  
    Others 142 228 60.6%
    (as % of sales) 2.6% 4.2%  
    Total 5,377 5,407 0.6%
    *(these numbers are based on USGAAP)

    Also, revenues from bulk drugs declined by 10% as both local as well global sales came down. The decline in international revenues from API was a factor of decline in revenues from the European market (down 58%), due to lower sales of 'Ramipril', which saw tough generic competition, and price decline. However, Dr. Reddy’s has shown better performance in the branded formulations segment, which has grown by 17.5% in the quarter, which is due to better performance in the Russian and CIS markets. However, domestic market performance saw a decline, led by fall in sales of high revenue generating products from key therapeutic areas of Gastro-intestinal, cardiovascular and anti-infectives.

    Operating margins:  The lacklustre topline performance has led to an even worse bottomline performance. The operating margin of the company has come down from 23.8% in the same quarter last year to 13.3% in 2QFY05. The major reason for this is higher other expenses and increase in R&D expenses. The R&D expenses of the company have grown by almost by 25% and are now 11% of revenues. The increased R&D expenses are due to the clinical trials of one of its molecules, which the company has initiated recently. Also, intense activity on ANDA front has lead to the increased spending. The other major factor for the poor operational performance is the sales and distribution expenses, which grew almost 29% during the quarter. However, the increase in both the above mentioned expense heads should be seen as an investment for future benefits.

    Cost break-up
      2QFY04 2QFY05 Change
    Raw material 1,625 1,617 -0.5%
    (as % of sales) 31.0% 30.9%  
    R&D expenses 447 560 25.4%
    (as % of sales) 8.5% 10.7%  
    Staff cost 632 731 15.6%
    (as % of sales) 12.1% 13.9%  
    Sales and distribution expenses 399 515 29.1%
    (as % of sales) 7.6% 9.8%  
    Other expenses 999 1,121 12.2%
    (as % of sales) 19.1% 21.4%  
    Total 4,102 4,545 10.8%

    Net profit:  Owing to the woes in topline, as well as in operating margins, the net profit of the company was down by 48% YoY. Lower other income due to loss on the forex side, as against gains last year has also contributed to the woes on the bottomline front. However, lower taxes on account of tax exemption due to higher R&D expenses and new bulk drugs facility in tax-exempted area has cushioned further slide in bottomline.

    What to expect?
    At Rs 721, the stock is trading at 44.1x its annualised 1HFY05 earnings. Looking at the current valuations, the stock might seem to be overvalued. However, the long-term prospects of the company look good. The last three quarters for the company have been very poor, both due to higher base effect, as well as investments made by the company on R&D front, and sales and distribution front. Off late, the company has changed its high-risk strategy of Para IV filings (to some extent) and is now considering other options such as entering into the specialty segment. As a result of its current efforts on the R&D and sales/distribution front, its long term prospects are likely to improve.



    Equitymaster requests your view! Post a comment on "Dr Reddy's: Yet another disappointment ". Click here!


    More Views on News

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Dr Reddy's: Major Business Segments Come Under Pressure (Quarterly Results Update - Detailed)

    Sep 12, 2016

    Dr Reddy's has announced the results for first quarter of FY17 (1QFY17). The company has reported decline in the sales by 13.9% YoY while net profits declined by 79.8 % YoY.

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 18, 2017 03:37 PM


    • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks


    Detailed Financial Information With Charts